CELLECT BIOTECH/S (NASDAQ:APOP) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.

Brokerages have set a 1 year consensus price objective of $14.00 for the company and are anticipating that the company will post ($0.28) earnings per share for the current quarter, according to Zacks. Zacks has also given CELLECT BIOTECH/S an industry rank of 101 out of 255 based on the ratings given to related companies.

Several analysts have weighed in on APOP shares. Zacks Investment Research upgraded shares of CELLECT BIOTECH/S from a “hold” rating to a “buy” rating and set a $8.25 price objective for the company in a research note on Thursday, May 31st. HC Wainwright reiterated a “buy” rating and issued a $14.00 price objective on shares of CELLECT BIOTECH/S in a research note on Tuesday, May 29th. Finally, ValuEngine upgraded shares of CELLECT BIOTECH/S from a “sell” rating to a “hold” rating in a research note on Wednesday, June 6th.

CELLECT BIOTECH/S traded down $0.32, hitting $5.00, during midday trading on Friday, MarketBeat.com reports. The company’s stock had a trading volume of 50,355 shares, compared to its average volume of 23,897. CELLECT BIOTECH/S has a 1-year low of $4.71 and a 1-year high of $13.50.

CELLECT BIOTECH/S (NASDAQ:APOP) last issued its quarterly earnings data on Thursday, August 9th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.03. equities research analysts expect that CELLECT BIOTECH/S will post -1 EPS for the current fiscal year.

A hedge fund recently bought a new stake in CELLECT BIOTECH/S stock. Sabby Management LLC bought a new stake in CELLECT BIOTECH/S (NASDAQ:APOP) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 243,980 shares of the company’s stock, valued at approximately $1,557,000. CELLECT BIOTECH/S makes up approximately 0.2% of Sabby Management LLC’s holdings, making the stock its 23rd biggest holding. Sabby Management LLC owned 4.48% of CELLECT BIOTECH/S as of its most recent SEC filing. Institutional investors own 6.22% of the company’s stock.

About CELLECT BIOTECH/S

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.

Featured Article: Average Daily Trade Volume – What You Need to Know

Get a free copy of the Zacks research report on CELLECT BIOTECH/S (APOP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CELLECT BIOTECH/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELLECT BIOTECH/S and related companies with MarketBeat.com's FREE daily email newsletter.